---
title: "Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab."
collection: publications
category: manuscripts
excerpt: 'We treated 28 HCC patients with durvalumab, tremelimumab and locoregional therapies. We performed a high-dimensional multiomics analysis including whole exome sequencing, single-cell RNA seq, CO-Detection by indEXing, flow cytometry and multiplex cytokine/chemokine analysis of patientsâ€™ blood and tumour samples and integrated this data to elucidate immune correlatives and response mechanisms.'
date: 2025-05-07
venue: 'Gut'
paperurl: 'https://gut.bmj.com/content/74/6/983'
citation: 'Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M., Bauer, K. C., Huang, P., Ma, C., Monge, C., Xie, C., Hrones, D., Duffy, A. G., Armstrong, P., Kocheise, L., Desmond, F., Buchalter, J., Galligan, M., Cantwell, C., Ryan, R., McCann, J., Bourke, M., Nicholas, R. M., McDermott, R., Awosika, J., Cam, M., Krebs, R., Budhu, A., Revsine, M., Figg, W. D., Kleiner, D. E., Redd, B., Wood, B. J., Wang, X. W., Korangy, F., Claassen, M., & Greten, T. F. (2025). Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab. Gut, 74 (6), 983-995.'
---
